NCT07209644Not yet recruiting
Catestatin as a Novel Biomarker for Cardiovascular and Microvascular Involvement in Systemic Sclerosis
Serum Catestatin in Systemic Sclerosis: Relations to Cardiovascular Involvement and Microvascular Alterations
Source: ClinicalTrials.gov · Last updated 7 Oct 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study investigates the relationship between serum catestatin levels and systemic sclerosis (SSc), with a focus on cardiovascular involvement and microvascular alterations, to determine catestatin's potential as a biomarker of disease activity and severity.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 70 (estimated)
- First submitted
- 29 Sept 2025
- Start date
- 1 Nov 2026
- Primary completion date
- 1 Nov 2027
- Lead sponsor
- Assiut University
- Diseases
- Systemic sclerosis (scleroderma)
- NCT number
- NCT07209644
What you commit to
- Study type: Observational
- Planned participants: 70
- From 1 Nov 2026 to the primary completion date, 1 Nov 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Other autoimmune disorders.
- Cardiovascular conditions not linked to systemic sclerosis.
- Comorbidities affecting catestatin metabolism (e.g., diabetes, chronic kidney disease, obesity).
Who the study is looking for
- Patients diagnosed with systemic sclerosis according to 2013 ACR-EULAR classification criteria.
- Age \>18 years.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.